How does Entresto work in the body?
Entresto (sacubitril/valsartan) is a heart-failure medicine that improves how the cardiovascular system handles salt and blood pressure. It combines two actions:
- Sacubitril inhibits neprilysin, an enzyme that breaks down natriuretic peptides (signals that promote salt/water excretion and help relax blood vessels).
- Valsartan blocks the angiotensin II type 1 (AT1) receptor, which reduces the effects of the renin-angiotensin system that normally causes vasoconstriction and increases sodium retention.
By combining these effects, Entresto increases beneficial peptide signaling while reducing angiotensin II signaling, helping lower cardiac workload and congestion.
What does neprilysin inhibition change (sacubitril)?
Neprilysin normally degrades natriuretic peptides. When sacubitril inhibits neprilysin, natriuretic peptide activity lasts longer, which tends to:
- increase natriuresis and diuresis (help the body excrete salt and water)
- promote vasodilation (help lower vascular resistance)
- reduce harmful remodeling signals over time
How does valsartan’s AT1 blockade contribute?
Valsartan prevents angiotensin II from activating AT1 receptors. That reduces:
- vasoconstriction (less narrowing of blood vessels)
- aldosterone-driven sodium and fluid retention
- downstream signaling that can contribute to worsening heart failure
What is the overall pharmacology people mean by “mechanism”?
Clinically, the combined drug effect is often described as shifting the balance of signaling toward:
- “good” natriuretic peptide pathways (longer-lasting vasodilatory and fluid-removal signals)
and away from:
- “bad” angiotensin II/AT1 pathways (less vasoconstriction and fluid retention)
Why does Entresto lower blood pressure and fluid overload?
The natriuretic-peptide effect supports salt and water loss, while AT1 blockade reduces fluid-retaining and vasoconstricting pathways. Together, these actions can reduce congestion and help lower blood pressure, which is a key goal in heart-failure treatment.
What’s the practical implication for patients?
Because it changes both fluid-handling and blood-vessel tone pathways, Entresto can improve symptoms and outcomes in appropriate heart-failure patients by reducing strain on the heart and lowering congestion risk.
Sources
No external sources were provided in your prompt.